Eli Lilly leads AI-driven human software revolution
Eli Lilly was framed as the primary beneficiary of a structural shift toward 'human software' and peptides, leveraging cash flow from GLP-1s and AI partnerships to build a massive healthcare moat.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.